Commercial Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies Pharmaceutical TechnologyNovartis' Q1 was hit by generics erosion, though its Avidity-bolstered pipeline is set for a robust future.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Novartis’ Q1 was hit by generics erosion, though its Avidity-bolstered pipeline is set for a robust future. Read full story Post navigation Previous: Arcera and Fosun sign MoU for neuroscience innovationNext: The strategic investments expanding CDMO capabilities for HPAPIs and ADCs Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026